Design Therapeutics (DSGN) Common Equity (2020 - 2021)
Historic Common Equity for Design Therapeutics (DSGN) over the last 2 years, with Q3 2021 value amounting to $391.6 million.
- Design Therapeutics' Common Equity changed N/A to $391.6 million in Q3 2021 from the same period last year, while for Sep 2021 it was $391.6 million, marking a year-over-year change of. This contributed to the annual value of -$11.3 million for FY2020, which is N/A changed from last year.
- Per Design Therapeutics' latest filing, its Common Equity stood at $391.6 million for Q3 2021.
- In the past 5 years, Design Therapeutics' Common Equity ranged from a high of $408.0 million in Q1 2021 and a low of -$11.3 million during Q4 2020